2025
Could psychedelics be fine-tuned to relieve anxiety but skip the ‘trip’?
Knox C, Kwan A. Could psychedelics be fine-tuned to relieve anxiety but skip the ‘trip’? Nature 2025, 639: 45-46. PMID: 39966585, DOI: 10.1038/d41586-025-00454-z.Peer-Reviewed Original Research
2023
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee T, Davoudian P, Sanacora G, Wilkinson S. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Drug Discovery Today 2023, 28: 103818. PMID: 37925136, DOI: 10.1016/j.drudis.2023.103818.Peer-Reviewed Original ResearchPsychiatric disordersLysergic acid diethylamideClinical trialsUS Clinical Trials RegistryClinical Trials RegistryPotential therapeutic effectsTrials RegistryTherapeutic effectPotential therapyTherapeutic agentsN-dimethyltryptamineAcid diethylamideLargest causePsychedelic compoundsDisordersPsychotherapeutic approachesSafety concernsTrialsPotential interactive effectsCutting-edge reviewPsychedelic substancesRegistryTherapyOn the Edges: The Ethics of Human Studies with Psychedelic Substances
da Costa S, Sofuoglu M. On the Edges: The Ethics of Human Studies with Psychedelic Substances. 2023, 153-171. DOI: 10.1007/978-3-031-14339-7_9.Peer-Reviewed Original ResearchClinical benefitLife-threatening conditionNovel pharmacological agentsAlcohol use disorderClinical studiesDepressive symptomsHuman studiesPharmacological agentsUse disordersMedical supervisionClassical psychedelicsTherapeutic potentialClinical researchPsychoactive effectsPsychedelic substancesControlled Substances ActHuman researchAccepted medical useConsistent evidenceDisordersPsychedelicsSubstances ActSchedule IMedical useRecreational use
2018
Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic
Sloshower J. Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic. 2018, 113-132. DOI: 10.1007/978-3-319-76720-8_7.ChaptersHealing paradigmPsychiatric practiceCurrent psychiatric practicePsychedelic substancesSymptom-focused treatmentEthical challengesReductionist tendenciesCritical dialogueHuman beingsPsychedelic medicineReflexive mannerModel clinicTherapeutic narrativesMental illnessParadigm integrationBiological paradigmMedical SciencesSufferingRelated practicesKnowledge generationPassive recipientsPracticeEnergetic domainsSuch challengesParadigm
2017
Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine
Fattore L, Piva A, Zanda M, Fumagalli G, Chiamulera C. Psychedelics and reconsolidation of traumatic and appetitive maladaptive memories: focus on cannabinoids and ketamine. Psychopharmacology 2017, 235: 433-445. PMID: 29178010, DOI: 10.1007/s00213-017-4793-4.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderSubstance use disordersMaladaptive memoriesPsychedelic effectsReconsolidation of maladaptive memoriesAppetitive memory reconsolidationMemory reconsolidationMDMA effectsMemory inhibitionReconsolidation processStress disorderKetamine effectsPsychedelic substancesBiobehavioral processesReconsolidationCannabinoidMDMASubstance effectsMemoryPsychedelicsDisordersKetamineClasses of drugsPotential therapeutic effectsPotential therapeutic use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply